Knowledge (XXG)

Drug Efficacy Study Implementation

Source đź“ť

144: 121: 35:
be efficacious as well as safe, was made part of US law. The DESI program was intended to classify all pre-1962 drugs that were already on the market as either effective, ineffective, or needing further study. The Drug Efficacy Study Implementation (DESI) evaluated over 3,000 separate products and
125: 87: 36:
over 16,000 therapeutic claims. By 1984, final action had been completed on 3,443 products; of these, 2,225 were found to be effective, 1,051 were found not effective, and 167 were pending.
129: 108:
Chhabra R, Kremzner ME, Kiliany BJ. FDA policy on unapproved drug products: past, present, and future. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1260-4.
215: 210: 181: 57: 200: 88:
FDA aims to remove unapproved drugs from market: Risk-based enforcement program focuses on removing potentially harmful products
40: 205: 67: 24: 103: 174: 28: 143: 167: 62: 104:
The Drug Efficacy Study of the National Research Council’s Division of Medical Sciences, 1966-1969
109: 151: 52: 194: 113: 39:
One of the early effects of the DESI study was the development of the
32: 155: 130:
United States Department of Health and Human Services
150:This United States government–related article is a 27:(FDA) in the 1960s after the requirement (in the 175: 8: 182: 168: 102:National Academies of Sciences archives. 79: 7: 140: 138: 58:Federal Food, Drug, and Cosmetic Act 154:. You can help Knowledge (XXG) by 128:from websites or documents of the 17:Drug Efficacy Study Implementation 14: 142: 124: This article incorporates 119: 41:Abbreviated New Drug Application 29:Kefauver-Harris Drug Control Act 68:Regulation of therapeutic goods 216:United States government stubs 86:Pharmacy Today. August 2008. 1: 23:) was a program begun by the 211:Food and Drug Administration 25:Food and Drug Administration 232: 137: 201:American medical research 206:Pharmaceuticals policy 126:public domain material 63:Inverse benefit law 163: 162: 223: 184: 177: 170: 146: 139: 123: 122: 90: 84: 231: 230: 226: 225: 224: 222: 221: 220: 191: 190: 189: 188: 135: 120: 99: 94: 93: 85: 81: 76: 49: 12: 11: 5: 229: 227: 219: 218: 213: 208: 203: 193: 192: 187: 186: 179: 172: 164: 161: 160: 147: 117: 116: 106: 98: 97:External links 95: 92: 91: 78: 77: 75: 72: 71: 70: 65: 60: 55: 53:Estes Kefauver 48: 45: 13: 10: 9: 6: 4: 3: 2: 228: 217: 214: 212: 209: 207: 204: 202: 199: 198: 196: 185: 180: 178: 173: 171: 166: 165: 159: 157: 153: 148: 145: 141: 136: 133: 131: 127: 115: 111: 107: 105: 101: 100: 96: 89: 83: 80: 73: 69: 66: 64: 61: 59: 56: 54: 51: 50: 46: 44: 42: 37: 34: 30: 26: 22: 18: 156:expanding it 149: 134: 118: 82: 38: 20: 16: 15: 31:) that all 195:Categories 74:References 114:15956239 47:See also 43:(ANDA). 112:  33:drugs 152:stub 110:PMID 21:DESI 197:: 132:. 183:e 176:t 169:v 158:. 19:(

Index

Food and Drug Administration
Kefauver-Harris Drug Control Act
drugs
Abbreviated New Drug Application
Estes Kefauver
Federal Food, Drug, and Cosmetic Act
Inverse benefit law
Regulation of therapeutic goods
FDA aims to remove unapproved drugs from market: Risk-based enforcement program focuses on removing potentially harmful products
The Drug Efficacy Study of the National Research Council’s Division of Medical Sciences, 1966-1969
PMID
15956239
public domain material
United States Department of Health and Human Services
Stub icon
stub
expanding it
v
t
e
Categories
American medical research
Pharmaceuticals policy
Food and Drug Administration
United States government stubs

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑